S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.
- Mechanism
- Curator reviewed · 1 reference
S-8510 is a BZD partial inverse agonist to the BZD site on the GABA-A receptors in the central nervous system. As an inverse agonist (which as a group elicit CNS effects such as insomnia, agitation, and proconvulsant behaviors), S-8510 functions as a negative modulator of the GABA-A receptor. S-8510, however, is a partial inverse agonist, which means it has a lower affinity for the BZD binding site than do full agonists, and studies in animals have shown that the drug does not induce convulsions or anxiety.
- Primary indication
- Investigated for use/treatment in alzheimer's disease and dementia.Curator reviewed
- Formula / weight
- C12H10N4O2 · 242.238 g/mol (avg)
- Code names
- SB-737552
Resolves to
ITPFSYAYHHPKRT-UHFFFAOYSA-NSMILESC1CC2=C(CO1)C1=C(NC(=N1)C1=NOC=C1)C=N2What you can answer from here — as of March 06, 2025
Which drugs share a target with S-8510, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account